Basilea gibt Zulassung von Antibiotikum Zevtera® in China zur Behandlung von ambulant und im Spital erworbener Lungenentzündung bekannt
November 06, 2020 01:15 ET
|
Basilea Pharmaceutica AG
National Medical Products Administration (NMPA) erteilt Basileas Partner CR Gosun eine Drug Approval LicenseBasilea erhält CHF 3 Mio. Meilensteinzahlung von CR Gosun Basel, 06. November 2020 ...
Draganfly to Provide Global Flight Services for Varigard™
October 29, 2020 09:15 ET
|
Draganfly Inc
Los Angeles, CA. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer within...
Draganfly to Host Shareholder Update Call Including Live Demo of its COVID-19 Focused Infectious Disease Screening Technology
October 28, 2020 09:15 ET
|
Draganfly Inc
Los Angeles, CA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer within the...
Basilea gibt Clinical Trial Collaboration and Supply Agreement mit Eli Lilly and Company für Ramucirumab für die laufende FIDES-03-Studie mit Derazantinib bei Magenkrebs bekannt
October 28, 2020 02:15 ET
|
Basilea Pharmaceutica AG
Basel, 28. Oktober 2020 Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass sie ein Clinical Trial Collaboration and Supply Agreement mit Eli Lilly and Company für den Einsatz des...
Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ramucirumab in the ongoing FIDES-03 study with derazantinib in gastric cancer
October 28, 2020 02:15 ET
|
Basilea Pharmaceutica AG
Basel, Switzerland, October 28, 2020 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company for...
Draganfly Announces the Vital Intelligence API for Telehealth Applications
October 27, 2020 09:15 ET
|
Draganfly Inc
Los Angeles, CA., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer and systems...
Christina Lake Cannabis Appoints Ryan Smith as Chief Financial Officer
October 27, 2020 09:00 ET
|
Christina Lake Cannabis Corp.
VANCOUVER, British Columbia, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Christina Lake Cannabis Corp. (the “Company” or “CLC” or “Christina Lake Cannabis”) is pleased to announce the appointment of Ryan...
Christina Lake Cannabis Completes Inaugural Harvest – Crop Exceeds Target by 44%, Reaching 32,500 kg
October 26, 2020 09:00 ET
|
Christina Lake Cannabis Corp.
VANCOUVER, British Columbia, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Christina Lake Cannabis Corp. (the “Company” or “CLC” or “Christina Lake Cannabis”), a federally licensed cultivator, processor and...
Basilea präsentiert präklinische Daten zur anti-angiogenen Aktivität von Derazantinib auf der ENA 2020
October 26, 2020 02:15 ET
|
Basilea Pharmaceutica AG
Basel, 26. Oktober 2020 Basilea Pharmaceutica AG (SIX: BSLN) berichtete heute, dass Daten zur anti-angiogenen Aktivität des Fibroblasten-Wachstumsfaktor Rezeptor (engl. FGFR) Inhibitors...
Basilea presents preclinical data on anti-angiogenic activity of derazantinib at ENA 2020
October 26, 2020 02:15 ET
|
Basilea Pharmaceutica AG
Basel, Switzerland, October 26, 2020 Basilea Pharmaceutica Ltd. (SIX: BSLN) today reported that data on the anti-angiogenic activity of the fibroblast growth factor receptor (FGFR) inhibitor...